ICS 2015 Scientific Podium Short Oral Session S34 - Pharmacotherapy for Overactive Bladder

Pharmacotherapy for Overactive Bladder

Scientific Podium Short Oral Session S34

Speakers
	Friday 9th October 2015
	09:00 - 10:30
	515ABC
M Masayuki Takeda ICS Chair S Sender Herschorn ICS Chair
Learning Objectives
To examine novel research findings in the field of Pharmacotherapy for Overactive Bladder. To discuss methodological challenges for conducting research in the field of Pharmacotherapy for Overactive Bladder. To discern the internal and external generalizability of these research results in order to implement changes in research methods or clinical practice within the participant's own setting.

Session Schedule

09:00

#487 Clinical efficacy and safety of a beta3-adrenoceptor agonist (mirabegron) and an antimuscarinic agent (imidafenacin) in female patients with overactive bladder: a randomized crossover study

Torimoto K¹, Matsushita C², Yamada A³, Goto D³, Matsumoto Y⁴, Hosokawa Y², Hirayama A⁵, Fujimoto K¹
1. Nara Medical University, 2. Tane General Hospital, 3. Hirao Hospital, 4. Hoshigaoka Medical Center, 5. Nara Hospital Kinki University Faculty of Medicine
Clinical Trial, Female, Overactive Bladder, Pharmacology, Prospective Study

09:07

#488 3 Years’ Experience of High Adherence Rate of Mirabegron in Patients with Overactive Bladder in Japan: comparison between gender, and between single and combined pharmacotherapies.

Uchiyama H¹, Takeda M², Mitsui T², Ihara T², Kobayashi H², Zakoji H², Taniguchi T³
1. Uchiyama Urology Clinic, 2. Department of Urology, University of Yamanashi, 3. Department of Nursing, University of Yamanashi
Overactive Bladder, Overactive Bladder, Overactive Bladder, Overactive Bladder, Pharmacology

09:15

#489 Objective efficacy of mirabegron on storage and voiding function in patients with overactive bladder that is unresponsive to antimuscarinic treatment, based on a urodynamic study

Matsukawa Y¹, Takai S¹, Matsuo K¹, Funahashi Y¹, Yoshino Y¹, Yamamoto T¹, Gotoh M¹
1. Department of Urology, Nagoya University Graduate School of Medicine, Japan
Detrusor Overactivity, Female, Overactive Bladder, Urgency/Frequency

09:22

#490 Safety and efficacy of mirabegron add-on treatment to solifenacin in incontinent OAB subjects with an inadequate response to initial 4-week solifenacin monotherapy

Drake M¹, Adil Esen A², Athanasiou S³, Herholdt C⁴, Kaper M⁵, Saleem T⁴, Huang M⁴, Siddiqui E⁴, MacDiarmid S⁶
1. Bristol Urological Institute, Bristol, UK, 2. Dokuz Eylül University, Izmir, Turkey, 3. University of Athens,"Alexandra" Hospital, Athens, Greece, 4. Astellas Pharma Europe Ltd, Chertsey, Surrey, UK, 5. Astellas Pharma Global Development, Leiden, Netherlands, 6. Alliance Urology Specialists, Greensboro, NC, USA
Detrusor Overactivity, Incontinence, Overactive Bladder

09:30

#491 Persistence with Mirabegron therapy for Overactive Bladder: A real life experience

Pindoria N¹, Malde S², Nowers J², Taylor C², Kelleher C¹, Sahai A²
1. St. Thomas Hospital NHS, 2. Guy's Hospital NHS
Overactive Bladder, Urgency Urinary Incontinence, Detrusor Overactivity, Questionnaire

09:37

#492 Mirabegron versus Tolterodine for the treatment of overactive bladder: A meta-analysis of five randomized controlled trials

Naser O¹, Elgebaly A², Elfil M³, Mahmoud A², Negida A⁴, Rashad Y⁴, Rashad M⁴, Abd Elsalam A E⁴, Elkohly S⁵, Abdelrahman A⁴, Gana B¹
1. West Wales general hospital, Carmarthen, UK, 2. Faculty of medicine, Al Azhar University, Cairo, Egypt, 3. Faculty of medicine, Alexandria University, Egypt, 4. Faculty of medicine, Zagazig University, Egypt, 5. Faculty of medicine, Cairo University, Egypt
Urgency Urinary Incontinence, Overactive Bladder, Detrusor Overactivity, Urgency/Frequency

09:45

#493 Longer-Term Outcomes of Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Single-Therapy Treatment

Ellington D¹, Malek J¹, Szychowski J², Kimberly G³, Burgio K⁴, Richter H¹
1. University of Alabama at Birmingham, Division of Urogynecology and Pelvic Reconstructive Surgery, 2. University of Alabama at Birmingham, Division of Biostatistics, 3. Park Nicollet Health, Urogynecology and Reconstructive Pelvic Surgery, 4. University of Alabama at Birmingham, Department of Medicine, Birmingham/Atlanta Geriatric Research, Education, and Clinical Center, Department of Veterans Affairs
Overactive Bladder, Clinical Trial, Quality of Life (QoL), Prospective Study

09:52

#494 Potential biomarkers for diagnosis and prediction of treatment efficacy in overactive bladder patients: urinary nerve growth factor, prostaglandin E2, and adenosine triphosphate

Suh Y S¹, Kim T H¹, Sung H H¹, Choo M², Lee J S³, Lee K¹
1. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., 2. Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, 3. Cheil General Hospital, Dankook University, College of Medicine, Seoul Korea
Overactive Bladder, Prospective Study, Biochemistry , Pharmacology, Urgency/Frequency

10:00

#495 Fesoterodine modulates the brain function in OAB patients: a real-time measure of oxyhemoglobin concentration changes during urodynamics

Sakakibara R¹, Tateno F¹, Tateno H¹, Kishi M¹, Tsuyusaki Y¹, Aiba Y¹, Yamamoto T², Yamanishi T³, Uchiyama T³, Shibata C³
1. Neurology, Internal Medicine, Sakura Medical Center, Toho University, 2. Neurology, Chiba University, 3. Continence Center, Dokkyo Medical College
Overactive Bladder, Gerontology, Imaging, Neuropathies: Central

10:07

#496 Adherence to anticholinergic agents by Japanese female OAB patients: patients of OAB wet and OAB dry

Hikita K¹, Honda M¹, Kawamoto B¹, Panagiota T², Muraoka K², Shimizu S³, Saito M³, Sejima T², Takenaka A²
1. Division of Urology, Department of Urology, Tottori University Faculty of Medicine, 2. Department of Urology, Tottori University Faculty of Medicine, 3. Department of Pharmacology, Kochi Medical School
Overactive Bladder, Female, Questionnaire

10:15

#497 Real life Management of flexible dose treatments with Fesoterodine and Solifenacin for overactive bladder patients

Arumi D¹, Sanchez-Ballester F², Garcia-Mediero J M³, Sanchez M⁴, Lizarraga I⁴
1. Unidad Médica, Pfizer Europe, Alcobendas. Madrid, 2. Hospital General de Valencia. Valencia, 3. Hospital MD Anderson. Madrid, 4. Unidad Médica, Pfizer SLU, Alcobendas. Madrid
Incontinence, Outcomes Research Methods, Overactive Bladder, Urgency/Frequency

10:22

#498 Economic impact of using fesoterodine for the treatment of overactive bladder in vulnerable elderly population in the United States

Qin L¹, Luo X², Zou K H², Snedecor S J¹
1. Pharmerit International, 2. Pfizer Inc
Overactive Bladder, Urgency Urinary Incontinence, Mathematical or statistical modelling, Outcomes Research Methods